Virginia Cancer Specialists
Oncology
Dr. Nicholas J. Robert, MD
Doctor Nicholas J. Robert, MD practices Oncology. He has 7 awards "America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:Washington-Baltimore", "Top Doctors:Washington DC Area", "Northern Virginia Magazine", "Redbook Magazine: Top Breast Cancer Doctors" and "Top MD". Nicholas J. Robert is a published doctor as well. He has 18 publications published. The latest was: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled,... He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled,...
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer.
- Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer...
- Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth ...
- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial.
- Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup...
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
- Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
- HER2-positive advanced breast cancer.
- Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
- Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
- The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
- Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Schools
McGill University Montreal
Royal Victoria Hospital
Massachusetts General Hospital
Brigham and Women39s Hospital
Dana Farber Cancer Institute
Doctors Specialties
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:Washington-Baltimore
- Top Doctors:Washington DC Area
- Northern Virginia Magazine
- Redbook Magazine: Top Breast Cancer Doctors
- Top MD
Education
-
Brigham and Women's Hospital
-
Massachusetts General Hospital
-
McGill University Faculty of Medicine
Hospital
-
Inova Alexandria Hospital
-
Inova Fair Oaks Hospital
-
Inova Fairfax Hospital
-
Novant Health Prince William Medical Center
Drug Facts
| NPI NUMBER |
|
1992772925 |
| NPPES Provider LastName |
|
ROBERT |
| NPPES Provider FirstName |
|
NICHOLAS |
| NPPES Provider ZIPCode |
|
220314629 |
| NPPES Provider State |
|
VA |
| Specialty Description |
|
Hematology/Oncology |
| Total Claim Count |
|
472.0 |
| Distinct Opioid Count |
|
1.0 |
| Opioid Claim Count |
|
17.0 |
| Percent Opioid Claims |
|
3.6 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1992772925 |
| Last Name Of The Provider |
ROBERT |
| First Name Of The Provider |
NICHOLAS |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.